Nuvation Bio Inc. (New York Stock Exchange:NUVB)
| Market Cap | $1.34B-48.7% |
| Revenue (ttm) | $201.73M+654.2% |
| Net Income | -$135.93M+37.5% |
| EPS | -$0.40+38.2% |
| Shares Out | 352.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,848,938 |
| Open | $3.76 |
| Previous Close | $3.81 |
| Day's Range | $3.73 - $3.91 |
| 52-Week Range | $3.71 - $9.75 |
| Beta | 1.73 |
| Analysts | Buy |
| Price Target | $17.00(+347.37%) |
| Earnings Date | Mar 1, 2027 |
About NUVB
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating NUVB in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 1, 2027Earnings report
$NUVB stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NUVB holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NUVB's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NUVB Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NUVB Revenue by Segment or Geography
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New NUVB patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NUVB from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NUVB
| VTIVanguard Morningstar Total Stock Market ETF | $33.37M |
| IWMiShares Russell 2000 ETF | $25.63M |
| VXFVanguard Extended Market ETF | $14.28M |
| IWOiShares Russell 2000 Growth ETF | $9.03M |
| IBBiShares Biotechnology ETF | $7.40M |
| VTWOVanguard Russell 2000 ETF | $7.05M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from NUVB’s recent data — informational, not investment advice
What’s Behind the Score
News check: Strong positive clinical data on safusidenib showing 81.5% benefit rate in glioma trial; mixed valuation commentary suggests established investor confidence.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 1.24% |
| BBP | Virtus Biotech ETF | 1.12% |
| PTH | Invesco Dorsey Wright Healthcare Momentum ETF | 1.08% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.93% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 0.93% |
| CANC | Tema Oncology ETF | 0.83% |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 0.37% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.28% |
| IWC | iShares Micro-Cap ETF | 0.27% |
| ACSG | American Century Small Cap Growth Insights ETF | 0.23% |
| IHE | iShares U.S. Pharmaceuticals ETF | 0.23% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.19% |
Weight is the stock’s share of each fund’s holdings.
